NJA-004

N/A

Report date: 2024/05/11 18:34:09

Base Information

Drug NameNJA-004

Drug Alias NameCD8⍺β T cell therapy(Shinobi Therapeutics)NJA-004

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionCD8A modulatorsT-cell surface glycoprotein CD8 beta chain modulators

TargetsT-cell surface glycoprotein CD8 beta chainT-cell surface glycoprotein CD8 alpha chain

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesShinobi Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesShinobi Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A